HomeCompareSMDPY vs DIVO

SMDPY vs DIVO: Dividend Comparison 2026

SMDPY yields 16.48% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DIVO wins by $8.3K in total portfolio value· pulled ahead in Year 2
10 years
SMDPY
SMDPY
● Live price
16.48%
Share price
$12.14
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$1.85
Full SMDPY calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — SMDPY vs DIVO

📍 DIVO pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMDPYDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMDPY + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMDPY pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMDPY
Annual income on $10K today (after 15% tax)
$1,400.91/yr
After 10yr DRIP, annual income (after tax)
$1.57/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, DIVO beats the other by $855.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMDPY + DIVO for your $10,000?

SMDPY: 50%DIVO: 50%
100% DIVO50/50100% SMDPY
Portfolio after 10yr
$26.8K
Annual income
$505.17/yr
Blended yield
1.88%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMDPY buys
0
DIVO buys
0
No recent congressional trades found for SMDPY or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMDPYDIVO
Forward yield16.48%6.62%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$22.6K$31.0K
Annual income after 10y$1.85$1,008.47
Total dividends collected$1.7K$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SMDPY vs DIVO ($10,000, DRIP)

YearSMDPY PortfolioSMDPY Income/yrDIVO PortfolioDIVO Income/yrGap
1$11,524$824.06$11,362$661.96+$162.00SMDPY
2← crossover$12,775$443.76$12,860$702.91$85.00DIVO
3$13,899$229.87$14,504$743.56$605.00DIVO
4$14,988$116.87$16,303$783.73$1.3KDIVO
5$16,096$58.89$18,268$823.31$2.2KDIVO
6$17,253$29.55$20,408$862.17$3.2KDIVO
7$18,475$14.80$22,737$900.20$4.3KDIVO
8$19,776$7.41$25,266$937.31$5.5KDIVO
9$21,164$3.70$28,008$973.42$6.8KDIVO
10$22,647$1.85$30,977$1,008.47$8.3KDIVO

SMDPY vs DIVO: Complete Analysis 2026

SMDPYStock

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Full SMDPY Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this SMDPY vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMDPY vs SCHDSMDPY vs JEPISMDPY vs OSMDPY vs KOSMDPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.